Transitioning From Brand to Generic With Topical Products and the Importance of Maintaining the Formulation and Therapeutic Profiles of the Original Product: Focus on Clocortolone Pivalate 0.1% Cream

July 2014 | Volume 13 | Issue 7 | Supplement Individual Articles | 77 | Copyright © July 2014

James Q. Del Rosso DO FAOCDa and Leon H. Kircik MDb

aLas Vegas Skin and Cancer Clinics/West Dermatology Group, JDRx Dermatology LL C, Henderson, NV;
Touro University College of Osteopathic Medicine, Henderson, NV
bIndiana University School of Medicine, Indianapolis, IN; Icahn School of Medicine at Mount Sinai, New York, NY;
Physicians Skin Care, PLL C, Louisville, KY

table 1
late 0.1% cream and HB-LC were comparable to each other, and superior to HB-L, in reducing TEWL, and that clocortolone pivalate 0.1% cream was superior to both HB-LC and HB-L in increasing skin hydration.26
Although, it is not possible to directly quantify the correlation between the magnitude of these results and differences observed in the clinical setting, these results did demonstrate that clocortolone pivalate 0.1% cream exhibits the ability to enhance SC permeability barrier function by reducing TEWL and increasing hydration, supporting the careful selection of vehicle excipients that are “barrier friendly.” Both the decrease in TEWL and increased skin hydration are advantageous when using a TCS product to treat eczematous and inflammatory der-